Breakout Bulletin: April 5-10

You’re busy. Between clinic, prior authorizations, and everything else on your plate, keeping up with dermatology’s pace of change isn’t easy. The Breakout Bulletin is here to make sure you don’t miss what actually matters — what’s new, what it means, and what’s worth changing in your practice.

This week, the signal is less about any single drug and more about a broader shift: dermatology is becoming more flexible, more patient-driven, and more comfortable with complexity.

The JAK Conversation Is Catching Up to Reality

For years, the boxed warning on JAK inhibitors has shaped prescribing behavior—often more than the underlying data. At AAD 2026, that narrative was directly challenged.

The key clarification is one many clinicians know but haven’t fully acted on: the safety signal behind the warning came from rheumatoid arthritis patients—not from atopic dermatitis trials. That distinction is beginning to reshape how clinicians assess risk in real-world practice.

There’s also a familiar precedent. Topical calcineurin inhibitors carried similar concerns decades ago, yet over time, clinical experience reframed those risks. Many see JAK inhibitors following a similar path.

At the same time, decision-making itself is evolving. As oral therapies improve, efficacy is no longer the sole driver. As Diego Ruiz Dasilva, MD, put it:

“I’m truly going to let the patients pick.”

When outcomes begin to converge, preference—pill vs injection, frequency, lifestyle—becomes clinically relevant, not secondary.

READ MORE: Contextualizing the JAK Inhibitor Black Box Warning in Dermatology

Convenience Is No Longer a Compromise

Treatment burden is quickly becoming a central part of the conversation.

New data on extended-interval biologics in atopic dermatitis suggest that durable control may be possible with just a few doses per year. Even more notable, responses didn’t just hold—they sometimes deepened over time, with complete clearance entering the discussion in a way not traditionally seen in AD.

That combination—durability, high efficacy, and infrequent dosing—has the potential to reshape expectations. Patients will increasingly ask for treatments that fit their lives, not just control their disease.

The question is no longer just “Does this work?” but “Does this work sustainably for this patient?”

READ MORE: Extended-Interval Dosing With Zumilokibart May Redefine AD Management

Dermatology Is Expanding Beyond the Skin

The growing interest in GLP-1 receptor agonists reflects a broader shift in how dermatology approaches disease.

These agents are not dermatology therapies—yet. But their anti-inflammatory effects, combined with their role in metabolic disease, are reinforcing what we already know: conditions like psoriasis and hidradenitis suppurativa are systemic.

READ MORE: Investigating the Use of GLP-1 Receptor Agonists in Psoriasis and Hidradenitis Suppurativa

Addressing underlying drivers such as obesity and insulin resistance may improve skin disease. Not consistently enough to replace biologics, but enough to matter.

For now, GLP-1s are best viewed as adjunctive tools, particularly in patients with metabolic comorbidities. But they signal a shift toward treating the whole patient, not just the skin.

They also come with practical considerations. Concerns like “Ozempic face” reflect rapid weight loss, not a drug-specific issue, and can be managed with appropriate counseling.

READ MORE: Daniel Walker, MD, FAAD, on a Multifaceted Care Model for GLP-1 Patients

Rare Disease Is Becoming Actionable

In indolent systemic mastocytosis, targeted therapy against the KIT D816V mutation is delivering durable improvements measured in years. For patients who previously had limited options, that’s a meaningful change.

But the more immediate implication is diagnostic. These patients often present first with skin findings, placing dermatology clinicians at the front line.

At the same time, awareness is growing around conditions like VEXAS syndrome, where patients may resemble familiar inflammatory diseases but fail standard therapies. In these cases, the issue isn’t treatment selection—it’s recognizing that the diagnosis itself may be wrong.

As therapies become more targeted, missing the diagnosis carries greater consequences.

READ MORE: Long-Term PIONEER Data Reinforce Avapritinib's Role in Indolent Systemic Mastocytosis

Some Diseases Still Don’t Give You Time to Wait

Even as innovation accelerates, there are areas where the biggest opportunity is simply acting sooner.

Primary cicatricial alopecias are one of them. Described as “trichologic emergencies,” these conditions can lead to permanent hair loss if not treated early. Once follicles are destroyed, the damage is irreversible.

And yet, delays remain common—driven by under-recognition, access barriers, and the lack of FDA-approved therapies.

The takeaway is simple: these are not cosmetic conditions. Treating them as such has real consequences.

READ MORE: Kristen Lo Sicco, MD, on the Urgent Need to Address and Treat Lichen Planopilaris

AI Is Coming—But It’s Not Ready to Replace You

New frameworks outlining the use of generative AI and digital twins suggest a future where treatment response can be simulated before a prescription is written.

In a specialty where therapy selection often involves trial-and-error, that’s a compelling idea. It may also accelerate research in rare diseases through synthetic control arms.

But the limitations are real: fabricated outputs, bias in training data, and a lack of robust validation.

For now, AI is a tool—not a decision-maker. Its value will depend on how carefully it’s integrated into clinical workflows.

READ MORE: Your Patient's Digital Twin Could Predict Their Psoriasis Response Before Treatment Starts

The Bigger Shift

Taken together, these changes point to a field moving away from rigid algorithms and toward more individualized, system-aware care.

Risk is being reframed rather than avoided. Treatment decisions are becoming more collaborative. And dermatology is increasingly intersecting with broader systemic health.

For NPs and PAs, that shift is especially relevant. You’re not just following pathways—you’re helping define them.